GSK’s Stiefel buy to face initial 20 July EC Phase I deadline
Global drug giant GlaxoSmithkline's plans to buy US dermatology company Stiefel Laboratories are expected to face an initial 20 July Phase I review deadline by the European Commission.Global drug giant GlaxoSmithkline's...To view the full article, register now.
Already a subscriber? Click here to view full article